Index Entries

Jill M. Ferdinands, Brian E. Dixon, Brian E. Dixon, Patrick K. Mitchell, Malini B. DeSilva, Stephanie A. Irving, Ned Lewis, Karthik Natarajan, Edward Stenehjem, Shaun J. Grannis, Jungmi Han, Charlene McEvoy, Toan C. Ong, Allison L Naleway, Sarah E. Reese, Peter J. Embi, Kristin Dascomb, Nicola P. Klein, Eric P. Griggs, I-Chia Liao, Duck-Hye Yang, William F. Fadel, Nancy Grisel, Kristin Goddard, Palak Patel, Kempapura Murthy, Rebecca Birch, Nimish R. Valvi, Julie Arndorfer, Ousseny Zerbo, Monica Dickerson, Chandni Raiyani, Jeremiah Williams, Catherine H. Bozio, Lenee Blanton, Ruth Link-Gelles, Michelle A. Barron, Manjusha Gaglani, Mark G. Thompson, and Bruce Fireman
October 3, 2022
BMJ (British Medical Journal)
Centers for Disease Control and Prevention (CDC)

Objective: To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, and by age and immunocompromised status…

Results: 45,903 people admitted to hospital with covid-19 (cases) were compared with 213,103 people with covid-like illness who tested negative for SARS-CoV-2 (controls), and 103,287 people admitted to emergency department or urgent care with covid-19 (cases) were compared with 531,168 people with covid-like illness who tested negative for SARS-CoV-2. In the omicron period, vaccine effectiveness against covid-19 requiring admission to hospital was 89% (95% confidence interval 88% to 90%) within two months after dose 3 but waned to 66% (63% to 68%) by four to five months. Vaccine effectiveness of three doses against emergency department or urgent care visits was 83% (82% to 84%) initially but waned to 46% (44% to 49%) by four to five months. Waning was evident in all subgroups, including young adults and individuals who were not immunocompromised; although waning was more in people who were immunocompromised. Vaccine effectiveness increased among most groups after a fourth dose in whom this booster was recommended.

Conclusions: Effectiveness of mRNA vaccines against moderate and severe covid-19 waned with time after vaccination.”

document
breakthrough cases,COVID-19,clinical cases,hospitalizations,vaccines,mRNA